The SELECT trial reveal that there are many mechanisms of semaglutide that could attribute for cardiovascular and obesity benefit (cardiovascular benefit, liver disease and inflammatory) independent of weight loss, ➡️hence this make it unwise to stop this medication once achieving target weight loss. ➡️Lack of heterogeneity in achieving primary composite endpoints within different subgroups ➡️achieving clinical significance and numerical reduction in all cause mortality. ➡️economical value is challenging ➡️previous supportive evidence for weight loss independent CVS protective actions of the GLP-1 agonist as in HARMONY Outcomes trial for Albiglutide in type 2 DM there was no body weight difference at 28 weeks, yet 22% reduction in MACE, driven by fewer MI events https://lnkd.in/e98ZtQGF
SELECT trial results presented at #AHA23 show in adults with overweight or obesity who do not have diabetes, semaglutide reduced the risk of major adverse cardiovascular events by 20%.